Skip to content
← All sectors
Enterprise & Industrial

Rebuilding Chemicals & Specialty Chemicals

India's chemical industry is the China+1 beneficiary everyone expected — yet capacity utilisation sits at 60–75%, EBITDA margins have compressed under Chinese overcapacity and dumping, and value creation has split sharply between a few winners and a stalled majority. The opportunity (a ~$31B import-substitution gap, export tailwinds) is real; capturing it needs an operating and capital rebuild, not just another new line.

The board-level pressures

Where the pressure sits

Margin compression from Chinese overcapacity, dumping and customer destocking, with pricing power eroding even in specialty segments.
Low and uneven capacity utilisation (averaging 60–75%, new lines far lower) ties up capital and depresses returns on recent capex.
Heavy dependence on imported feedstocks and intermediates contributes to a large structural trade deficit and exposes cost to volatility.
Rising compliance burden — BIS Quality Control Orders on 150+ products, plus REACH and other export-market regulations — raises cost and complexity, especially across multi-product sites.
Backward integration and downstream value-added expansion need significant capex and working capital the firm must fund and sequence carefully amid uncertainty.
Commercial functions are relationship-and-distributor-led with weak digital demand generation, key-account management and export-market development.
How we rebuild it

The rebuild, system by system

Capital allocation & governanceRebuild capital allocation and the capex/backward-integration roadmap — sequencing import-substitution and downstream value-added investments against utilisation, working-capital and funding reality.
Commercial engine & key accountsBuild a modern commercial engine — key-account management, export-market development, and digital lead generation — to defend pricing on value rather than compete purely on commodity rate.
Org design, talent & capabilityStrengthen R&D, process-engineering, EHS and regulatory-affairs capability and org design so the firm can move up the value chain and stay continuously compliant.
Market positioning & reputationPosition the company on quality, reliability, sustainability and compliance credentials that China+1 buyers and regulated export markets actually screen for.
Leadership, succession & decisionsModernise governance and decision architecture in promoter-led groups so capital and commercial decisions are data-driven and not bottlenecked at the top.
Demand generation & digital GTMBuild technical marketing and export demand generation — application-led content, global buyer outreach — to win the China+1 diversification mandates flowing to India.
The digital & AI layer

Built over your systems, not beside them

ERP / MES / QMS / LIMS-aware — a roadmap that gives leadership a single, real-time view and compounds after we step back.

A unified plant-and-margin data layer over ERP/process systems giving real-time visibility of utilisation, batch cost, yield and product-line profitability.
AI-assisted formulation and process optimisation to shorten development cycles and improve yield and consistency.
Digital EHS and regulatory-compliance management (BIS QCO, REACH, audit trails) to reduce compliance risk across multi-product sites.
Demand-and-price scenario modelling against feedstock volatility and competitor capacity to guide commercial and capex timing.
Export-market intelligence and key-account CRM to systematically develop China+1 and import-substitution demand.
The opportunity

The value on the table

Directional, not promises — the specific targets get set in the diagnostic, against your numbers.

The ~$31B import-substitution gap is a direct, fundable growth arena for firms that sequence backward integration well.
China+1 diversification is steering global buyers to India — winnable by manufacturers who can prove quality, compliance and reliability.
Moving from commodity to value-added/specialty and downstream products structurally lifts margin away from dumping pressure.
Lifting utilisation on existing and new lines recovers returns already committed in capex.
Green chemistry, bio-based and sustainable product lines tap a fast-growing, premium, export-relevant segment.
How we'd work with you

We run an executive Transformation Diagnostic across leadership, operations, commercial engine, compliance and capital position, then deliver a prioritised roadmap — margin defence, utilisation, capex sequencing and commercial rebuild — and partner through execution and capability transfer.

← See other sectors